Devlin Brings Significant Expertise in Commercialization, Sales and Marketing

TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that Jodi Devlin has joined the Company as President of TriSalus Therapeutics.

In this newly established role, Ms. Devlin will be responsible for developing and executing the go-to-market strategy for TriSalus’ SD-101 therapeutic candidate, building the Company’s therapeutic marketing operations, working with the clinical team to incorporate commercial and payor needs into the clinical strategy, developing and executing the Company’s patient access and payor engagement strategy and developing a distinctive patient experience for the SD-101 treatment.

“We are fortunate to have someone of Jodi’s caliber lead our therapeutics team,” said Mary Szela, President and CEO of TriSalus. “Jodi brings three decades of industry experience, developing strategies and overseeing the successful commercialization and launch of numerous drug candidates. We look forward to benefiting from her leadership as she works with our clinical team to develop a distinctive patient experience and execute a go-to-market strategy for our SD-101 treatment.”

“I was drawn to TriSalus because of the Company’s unique, integrated approach to treating liver and pancreatic tumors, addressing immune dysfunction by combining immunotherapy drugs with highly effective drug delivery technology to better help patients,” said Ms. Devlin. “TriSalus’ disruptive technology and immunotherapeutic platform is producing encouraging data in clinical trials, and I’m pleased to be joining the Company at this time. I look forward to working with Mary, Dr. Katz and the clinical team to support the Company’s work to bring hope and improved treatments to the lives of patients.”

About Jodi Devlin

Ms. Devlin bring over 34 years of experience in biopharmaceuticals to TriSalus. Most recently, she served as Chief Executive Officer of AltaThera Pharmaceuticals, a precision medicine company using innovative science to improve patient care and solve serious and costly problems, where she built the Company’s vision and strategy, executed its turnaround, and oversaw the FDA approval of its product. Prior to serving as CEO, she held the role of Chief Commercial Officer at AltaThera, overseeing sales, marketing, pricing, reimbursement, and health economics. Prior to that, Ms. Devlin served as the Vice President and General Manager of the Hospital Acute Care business at Mallinckrodt Pharmaceuticals, a global specialty pharmaceutical company, where she led the strategy and commercialization of Ofirmev, a non-opioid pain drug, and surgical hemostats. Ms. Devlin has also served as a Senior Executive at Baxter/Baxalta, a global, diversified healthcare company developing, manufacturing and marketing products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions, and Abbott AbbVie, a pharmaceutical company that discovers and delivers innovative medicines, where she led the commercialization, launch and clinical strategy for over 20 products, including the Company’s flagship product HUMIRA. She currently serves on the Board of Directors of Fitabeo Therapeutics, a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems.

Ms. Devlin holds a Bachelor of Science in Nursing degree from Oklahoma University and a Master of Business Administration from Washington University’s Olin School of Business.

About TriSalus Life Sciences

TriSalus Life Sciences® is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.

The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230905090653/en/